Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Allergan : Trump to keep Obama rule curbing corporate tax inversion deals

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 04:55pm CET
U.S. President Donald Trump departs Washington aboard Air Force One

(This October 4 story fixes comment by Organization for International Investment as referring to historically foreign-based companies in paragraph 13.)

President Donald Trump ordered a review almost six months ago of tax rules from the final months of the Obama administration, including ones to discourage companies from redomiciling abroad for tax reasons.

"Treasury plans to retain the distribution requirements under Section 385 pending enactment of tax reform," the department said in a statement, adding "these regulations are necessary to safeguard against earnings stripping."

It also said it planned to revoke and streamline some related documentation rules.

A 2011-2015 wave of inversion deals prompted Treasury to take a series of actions that culminated in an April 2016 rule release and the collapse of a $160-billion deal between U.S. drugmaker Pfizer Inc (>> Pfizer) and Ireland’s Allergan Plc (>> Allergan plc), which would have been the largest inversion ever.

Tax inversions occur when a U.S. company is acquired by a smaller foreign business from a low-tax country and adopts its domicile to reduce the combined firm’s overall U.S. tax burden.

The Section 385 rule was part of Obama's anti-inversion effort and was finalized a year ago. It was meant to combat a corporate tax-reduction technique known as earnings stripping.

Earnings stripping occurs when the U.S. subsidiary of a newly inverted company loads up on debt and avoids taxes on its domestic profits by sending them overseas to the foreign parent in the form of tax-deductible interest payments.

The Obama rule reclassified some forms of debt as equity, changing tax-exempt interest payments into taxable dividends and making earnings stripping strategies more difficult to pursue.

The Organization for International Investment (OFII), a Washington lobbying group for foreign-based companies with U.S. operations, praised the documentation portion of Treasury's latest move and criticized the retention of the rest of the Section 385 rule.

"Unfortunately, in perpetuating an unsubstantiated premise of the Obama administration, Treasury has decided to keep part of these discriminatory regulations," the group said.

Companies with historic foreign headquarters that have expanded into the United States, OFII said in a statement, "are not overleveraged, their debt levels have remained largely flat and their interest expense has declined while their investments into America’s economy have grown."

The Treasury Department said it expected a Republican proposal to overhaul the tax code would eliminate the need for anti-inversion rules. The proposal would sharply cut the corporate tax rate and end taxation of multinationals' foreign profits.

(Writing by Kevin Drawbaugh; Editing by Susan Thomas)

Stocks treated in this article : Allergan plc, Pfizer
Stocks mentioned in the article
ChangeLast1st jan.
PFIZER 1.46% 36.26 Delayed Quote.-1.33%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ALLERGAN PLC
02/23ALLERGAN : An Application for the Trademark "PYLERA" Has Been Filed by Allergan
02/23ALLERGAN : FDA Acceptance of Medicines360's Filing for supplemental New Drug App..
02/22ALLERGAN : FDA Acceptance of Medicines360's Filing for supplemental New Drug App..
02/20ALLERGAN : Presents Data at the 2018 American Academy of Dermatology Annual Meet..
02/17ALLERGAN : Presents Data at the 2018 American Academy of Dermatology (AAD) Annua..
02/15ALLERGAN : Trademark Application for "REJUVACROSS" Filed by Allergan
02/15ALLERGAN : An Application for the Trademark "REJUVECROSS" Has Been Filed by Alle..
02/15ALLERGAN : Matthew M. Walsh Appointed Executive Vice President and Chief Financi..
02/14ALLERGAN : s Forest Labs pays 726m in dividend
More news
News from SeekingAlpha
02/24Patent Office Puts Allergan's Mohawk Deal Out Of Its Misery 
02/23Tracking Larry Robbins' Glenview Capital Management Portfolio - Q4 2017 Updat.. 
02/23Will Analysts Abandon Allergan On Esmya Headwinds? 
02/23Premarket analyst action - healthcare 
02/22Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q4 2017 Upda.. 
Financials ($)
Sales 2018 15 196 M
EBIT 2018 7 274 M
Net income 2018 -1 246 M
Debt 2018 22 990 M
Yield 2018 1,83%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,00x
EV / Sales 2019 4,66x
Capitalization 53 014 M
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 216 $
Spread / Average Target 35%
EPS Revisions
Brenton L. Saunders Chairman, President & Chief Executive Officer
Matthew M. Walsh Chief Financial Officer & Executive VP
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
James H. Bloem Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC-2.56%53 014
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%222 939
PFIZER-1.33%213 155
ROCHE HOLDING LTD.-9.41%207 036
MERCK AND COMPANY-3.02%148 618